Sana Biotechnology Future Growth
Future criteria checks 0/6
Sana Biotechnology is forecast to grow earnings and revenue by 3.9% and 88.3% per annum respectively. EPS is expected to grow by 14.7% per annum. Return on equity is forecast to be -66.3% in 3 years.
Key information
3.9%
Earnings growth rate
14.7%
EPS growth rate
| Biotechs earnings growth | 27.6% |
| Revenue growth rate | 88.3% |
| Future return on equity | -66.3% |
| Analyst coverage | Low |
| Last updated | 27 Nov 2024 |
Recent future growth updates
Recent updates
Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus
Dec 04Sana Biotechnology: The Story Becomes Murkier
Nov 19We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully
Nov 01
Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline
Jul 14We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate
Jul 12Sana Biotechnology: Now In Overbought Territory
Mar 17Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)
Jan 11Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?
Dec 30Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation
Sep 14Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?
May 26We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate
Dec 19Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation
Sep 03Sana Biotechnology A Buy For Potential Cancer Therapies
Jun 27Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?
May 16Sana Biotechnology: Exciting Preclinical Science
Feb 12Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?
Oct 13Sana Biotechnology: Hypoimmune Cell Therapies
Jul 01Sana Biotechnology reports Q1 results
May 05Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -213 | -177 | -143 | 4 |
| 12/31/2025 | N/A | -198 | -159 | -144 | 4 |
| 12/31/2024 | N/A | -267 | -232 | -210 | 4 |
| 9/30/2024 | N/A | -306 | -275 | -228 | N/A |
| 6/30/2024 | N/A | -245 | -285 | -240 | N/A |
| 3/31/2024 | N/A | -309 | -274 | -240 | N/A |
| 12/31/2023 | N/A | -283 | -274 | -254 | N/A |
| 9/30/2023 | N/A | -276 | -288 | -278 | N/A |
| 6/30/2023 | N/A | -362 | -292 | -279 | N/A |
| 3/31/2023 | N/A | -320 | -307 | -292 | N/A |
| 12/31/2022 | N/A | -269 | -311 | -290 | N/A |
| 9/30/2022 | N/A | -300 | -346 | -324 | N/A |
| 6/30/2022 | N/A | -298 | -335 | -310 | N/A |
| 3/31/2022 | N/A | -207 | -310 | -279 | N/A |
| 12/31/2021 | N/A | -356 | -281 | -251 | N/A |
| 9/30/2021 | N/A | -358 | -212 | -179 | N/A |
| 6/30/2021 | N/A | -327 | -198 | -166 | N/A |
| 3/31/2021 | N/A | -433 | -183 | -158 | N/A |
| 12/31/2020 | N/A | -285 | -162 | -138 | N/A |
| 9/30/2020 | N/A | -215 | -155 | -134 | N/A |
| 12/31/2019 | N/A | -131 | -112 | -86 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SANA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SANA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SANA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SANA is forecast to have no revenue next year.
High Growth Revenue: SANA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SANA is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 01:40 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sana Biotechnology, Inc. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Alec Stranahan | BofA Global Research |
| Samantha Lynn Semenkow | Citigroup Inc |